Research Article
Validation of the EBMT Risk Score for South Brazilian Patients Submitted to Allogeneic Hematopoietic Stem Cell Transplantation
Table 1
Patients distribution.
| | Category | AML | ALL | CML | MDS | MM | LD | SAA | Total |
| | Sex | | Male | 33 (55.9%) | 30 (62.5%) | 45 (59.2%) | 6 (37.5%) | 1 (100%) | 12 (44.4%) | 29 (56.9%) | 156 (56.1%) | | Female | 26 (44.1%) | 18 (37.5%) | 31 (40.8%) | 10 (62.5%) | 0 | 15 (55.6%) | 22 (43.1%) | 122 (43.9%) |
| | Source | | BM | 49 (83.1%) | 41 (85.4%) | 63 (82.9%) | 11 (68.8%) | 0 | 7 (25.9%) | 49 (96.1%) | 220 (79.1%) | | PBSC | 10 (16.9%) | 3 (6.3%) | 13 (17.1%) | 4 (25%) | 1 (100%) | 20 (74.1%) | 1 (2%) | 52 (18.7%) | | CB | 0 | 4 (8.3%) | 0 | 1 (6.3%) | 0 | 0 | 1 (2%) | 6 (2.2%) |
| | Regimen | | Myeloablative | 58 (98.3%) | 48 (100%) | 76 (100%) | 12 (75%) | 0 | 0 | 46 (90.2%) | 241 (86.7%) | | RIC | 1 (1.7%) | 0 | 0 | 4 (25%) | 1 (100%) | 27 (100%) | 5 (9.8%) | 37 (13.3%) |
| | Patient age | | Median | 35 | 15 | 36.5 | 35 | 31 | 43 | 20 | 32 | | Range | 1–55 | 1–47 | 7–57 | 2–55 | 31 | 18–56 | 5–51 | 1–57 |
| | Age | | <20 | 14 (23.7%) | 27 (56.3%) | 6 (7.9%) | 4 (25%) | 0 | 2 (7.4%) | 26 (51%) | 79 (28.4%) | | 20–40 | 27 (45.8%) | 16 (33.3%) | 40 (52.6%) | 6 (37.5%) | 1 (100%) | 10 (37%) | 19 (37.3%) | 119 (42.8%) | | >40 | 18 (30.5%) | 5 (10.4%) | 30 (39.5%) | 6 (37.5%) | 0 | 15 (55.6%) | 6 (11.8%) | 80 (28.8%) |
| | Disease stage | | Early | 28 (47.5%) | 18 (37.5%) | 60 (78.9%) | 16 (100%) | 0 | 2 (7.4%) | 51 (100%) | 175 (62.9%) | | Intermediate | 17 (28.8%) | 23 (47.9%) | 12 (15.8%) | 0 | 1 (100%) | 7 (25.9%) | — | 60 (21.6%) | | Advanced | 14 (23.7%) | 7 (14.6%) | 4 (5.3%) | 0 | 0 | 18 (66.7%) | — | 43 (15.5%) |
| | Time interval | | <12 months | 24 (40.7%) | 13 (27.1%) | 13 (17.1%) | 5 (31.3%) | 0 | 1 (3.7%) | 36 (70.6%) | 92 (33.1%) | | >12 months | 35 (59.3%) | 35 (72.9%) | 63 (82.9%) | 11 (68.7%) | 1 (100%) | 26 (96.3%) | 15 (29.45) | 186 (66.9%) |
| | HLA | | HLA IS | 50 (84.7%) | 33 (68.8%) | 69 (90.8%) | 14 (87.5%) | 1 (100%) | 27 (100%) | 44 (86.3%) | 238 (85.6%) | | Unrelated | 9 (15.35) | 15 (31.3%) | 7 (9.2%) | 2 (12.5%) | 0 | 0 | 7 (13.7%) | 40 (14.4%) |
| | Gender com | | Other | 42 (71.2%) | 34 (70.8%) | 58 (76.3%) | 16 (100%) | 0 | 21 (77.8%) | 38 (74.5%) | 209 (75.2%) | | DF/RM | 17 (28.8%) | 14 (29.2%) | 18 (23.7%) | 0 | 1 (100%) | 6 (22.2%) | 13 (25.5%) | 69 (24.8%) |
| | Score | | 0 | 2 (3.4%) | 4 (8.3%) | 1 (1.3%) | 2 (12.5%) | 0 | 0 | 13 (25.5%) | 22 (7.9%) | | 1 | 10 (16.9%) | 6 (12.5%) | 7 (9.2%) | 4 (25%) | 0 | 0 | 18 (35.3%) | 45 (16.2%) | | 2 | 17 (28.8%) | 12 (25%) | 20 (26.3%) | 3 (18.8%) | 0 | 1 (3.7%) | 13 (25.5%) | 66 (23.7%) | | 3 | 9 (15.3%) | 12 (25%) | 35 (46.1%) | 7 (15.3%) | 0 | 3 (11.1%) | 6 (11.8%) | 72 (25.9%) | | 4 | 10 (16.9%) | 11 (22.9%) | 9 (11.8%) | 0 | 1 (100%) | 11 (40.7%) | 1 (2.0%) | 43 (15.5%) | | 5 | 8 (13.6%) | 2 (4.2%) | 4 (5.3%) | 0 | 0 | 11 (40.7%) | 0 | 25 (9.0%) | | 6 | 3 (5.1%) | 1 (2.1%) | 0 | 0 | 0 | 1 (3.7%) | 0 | 5 (1.8%) |
| | CMV | | Recipient pos | 52 (91.2%) | 37 (77.1%) | 65 (85.5%) | 14 (87.5%) | 1 (100%) | 23 (88.5%) | 46 (90.2%) | 238 (86.5%) | | Recipient neg | 5 (8.8%) | 11 (22.9%) | 11 (14.5%) | 2 (12.5%) | 0 | 3 (11.5%) | 5 (9.8%) | 37 (13.5%) |
|
|
AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CML: chronic myeloid leukemia; MDS: myelodysplastic syndrome; MM: multiple myeloma; LD: lymphoproliferative disorders; SAA: severe aplastic anemia; BM: bone marrow; PBSC: peripheral blood stem cell; CB: cord blood; HLA IS: human leukocyte antigen identical sibling; Gender com: gender combination between donor and recipient; DF/RM: donor female/recipient male; CMV: cytomegalovirus; neg: negative; pos: positive.
|
